NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
- Dave Knapp
- Feb 27
- 1 min read
On this episode of On the Pen, Dave breaks down Novo Nordisk’s decision to slash list prices for Wegovy and Ozempic starting in 2027, alongside new head-to-head data showing tirzepatide outperforming Novo’s next-gen combo CagriSema in weight loss. Dave also explores promising early results from triple-agonist drugs and the FDA approval of the Allurion Balloon, highlighting how the obesity treatment landscape is rapidly expanding beyond injections toward more personalized and accessible options.
What are your thoughts about this data drop and the Allurion Balloon?
This article is reader-supported on Substack.
To receive new posts and support my work,
consider becoming a free or paid subscriber.
Hey everyone! I play occasionally, mostly when there’s a football match I already planned to watch. Sports betting can make the game a bit more exciting, while online casino games are something I approach more cautiously. I’ve also noticed that platforms such as https://casinoo.games/ combine Casino Online entertainment with sports betting, so there’s plenty of choice in one place. For me, though, the key is setting a fixed budget beforehand and treating any bet as entertainment rather than a way to earn money. Curious how often you guys play and whether you prefer sports bets or casino games?
I like that Drive Mad focuses on skill rather than complicated mechanics. A few minutes of play can quickly turn into a full session.